Lantheus Holdings, Inc. (NASDAQ:LNTH) is a company involved in the development and commercialization of diagnostic medical imaging agents and products. It operates in the healthcare sector, providing essential tools for medical professionals to diagnose and treat diseases. The company faces competition from other firms in the medical imaging industry, but it continues to hold a significant market position.
On December 11, 2025, Richard Newitter from Truist Financial set a price target of $80 for LNTH. At that time, the stock was priced at $63.09, suggesting a potential increase of about 26.8% to reach the target. This optimistic outlook comes despite the ongoing investigation by Grabar Law Office into potential breaches of fiduciary duties by certain officers and directors of Lantheus.
The investigation, as highlighted by Grabar Law Office, is part of a broader federal securities fraud class action complaint against Lantheus. Shareholders who bought shares before November 6, 2024, and still hold them, may seek corporate reforms and financial restitution. This legal scrutiny could impact investor confidence, yet the stock has shown resilience with a 3.73% increase, reaching $63.09.
LNTH's stock has experienced fluctuations, trading between $61.21 and $63.195 during the day. Over the past year, it has seen a high of $111.29 and a low of $47.25. Despite the legal challenges, the company maintains a market capitalization of approximately $4.32 billion, indicating its substantial presence in the market.
The trading volume for LNTH on the NASDAQ exchange is 914,143 shares, reflecting active investor interest. While the investigation may pose risks, the stock's recent performance and the positive price target set by Truist Financial suggest potential growth opportunities for Lantheus Holdings.
